Alumis Inc
ALMS4.720USD
0.000
收盘 11/07, 16:00（美东）报价延迟15分钟
491.08M总市值
亏损市盈率 TTM
关于 Alumis Inc 公司
Alumis Inc. 是一家临床阶段的生物制药公司。该公司开发了两种酪氨酸激酶 2 (TYK2) 抑制剂：ESK-001，一种第二代抑制剂，该公司正在开发该抑制剂以最大限度地抑制靶标并优化耐受性，以及 A-005，一种中枢神经系统 (CNS) 渗透性分子。该公司建立了一系列分子，有可能作为单一疗法或联合疗法治疗一系列免疫介导疾病。ESK-001 是一种变构 TYK2 抑制剂，用于治疗斑块状银屑病、系统性红斑狼疮和葡萄膜炎。A-005 是一种 CNS 渗透性变构 TYK2 抑制剂，可在 CNS 内提供 TYK2 抑制的治疗益处，用于治疗一系列神经炎症和神经退行性疾病。该公司拥有多项早期发现资产，例如其数据分析平台确定的靶标，可用于治疗免疫介导的适应症。其数据分析证明了中枢神经系统疾病中 TYK2 抑制的遗传原理。
Alumis Inc简介
公司代码ALMS
公司名称Alumis Inc
上市日期Jun 28, 2024
CEOMr. Martin Babler
员工数量168
证券类型Ordinary Share
年结日Jun 28
公司地址280 East Grand Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16502316625
网址https://www.alumis.com/
公司代码ALMS
上市日期Jun 28, 2024
CEOMr. Martin Babler
Alumis Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
收入明细
FY2025Q2
FY2025Q1
暂无数据
地区USD
名称
营收
占比
United States
2.67M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Ayur Maya Capital Management Company, L.P.
15.63%
Foresite Capital Management, LLC
10.35%
Samsara BioCapital, LLC
4.96%
VenBio Partners LLC
4.77%
The Vanguard Group, Inc.
4.16%
其他
60.14%
持股股东
持股股东
占比
Ayur Maya Capital Management Company, L.P.
15.63%
Foresite Capital Management, LLC
10.35%
Samsara BioCapital, LLC
4.96%
VenBio Partners LLC
4.77%
The Vanguard Group, Inc.
4.16%
其他
60.14%
股东类型
持股股东
占比
Private Equity
34.07%
Investment Advisor
16.05%
Hedge Fund
12.54%
Investment Advisor/Hedge Fund
9.97%
Venture Capital
7.65%
Individual Investor
0.82%
Research Firm
0.78%
Bank and Trust
0.48%
Pension Fund
0.04%
其他
17.59%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
192
79.50M
82.06%
+19.19M
2025Q2
152
55.51M
57.84%
+13.35M
2025Q1
136
45.24M
77.97%
+3.71M
2024Q4
112
45.08M
95.45%
+8.63M
2024Q3
90
35.83M
75.90%
+3.97M
2024Q2
36
30.85M
69.04%
+30.85M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Ayur Maya Capital Management Company, L.P.
15.14M
15.63%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
10.03M
10.35%
-5.17M
-34.02%
Jun 30, 2025
Samsara BioCapital, LLC
4.80M
4.96%
--
--
Jun 30, 2025
VenBio Partners LLC
4.62M
4.77%
+1.83M
+65.74%
Jun 30, 2025
The Vanguard Group, Inc.
3.40M
3.51%
+2.47M
+263.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.81M
3.93%
+2.46M
+182.05%
Jun 30, 2025
Trium Capital LLP
2.65M
2.73%
+2.65M
--
Jun 30, 2025
Nextech Invest, Ltd.
2.92M
3.01%
+1.44M
+97.43%
Jun 30, 2025
Cormorant Asset Management, LP
2.15M
2.22%
--
--
Jun 30, 2025
Tang Capital Management, LLC
2.00M
2.06%
+2.00M
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
ProShares Ultra Nasdaq Biotechnology
占比0.04%
iShares Micro-Cap ETF
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
iShares Biotechnology ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
iShares Russell 2000 ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
Global X Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
